FNY Investment Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

FNY Investment Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-125	Closed	-$1K	–	663
2018 Q3	$1K	Buy	+125	New	+$1.01K	﹤0.01%	763

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

FNY Investment Advisers's ALDX Position: Q4 2020 in Review

FNY Investment Advisers sold out of Aldeyra Therapeutics (ALDX) in Q4 2020, closing a stake of 100 shares.

FNY Investment Advisers first reported a position in ALDX in Q2 2018 and held it in 7 quarters. The position peaked at $419K in Q3 2018. 98 funds tracked by Wall St. Rank hold ALDX as of Q4 2020.

FNY Investment Advisers reported no remaining Aldeyra Therapeutics position as of Q4 2020 after selling out during the quarter.
FNY Investment Advisers sold 100 Aldeyra Therapeutics shares in Q4 2020.
FNY Investment Advisers first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 7 quarters.
FNY Investment Advisers's Aldeyra Therapeutics position peaked at $419K in Q3 2018.
98 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2020.

Based on FNY Investment Advisers's 13F filing for Q4 2020, filed 19 Jan 2021.